

BC BLOOD CANCER AM AWARENESS MONTH



MULTIPLE MYELOMA: AFTER RELAPSE, EVERY DECISION SHAPES WHAT COMES NEXT

01 | RELAPSE IS NOT ONE MOMENT

Multiple myeloma is characterized by repeated cycles of response and relapse. But each relapse may represent a biologically different disease state.

Prior treatment exposure, refractoriness, duration of the previous response, cytogenetic risk, disease tempo, comorbidities and patient preference can all influence the next therapeutic decision.



AT RELAPSE, ASK MORE THAN: “WHAT TREATMENT COMES NEXT?”

- What has the disease already seen?
- What is it refractory to?
- How quickly is it progressing?
- What treatment experience matters to this patient?


Current guidelines emphasize individualized treatment selection based on prior therapy, refractoriness, fitness, disease characteristics and available therapeutic classes.

02 | BCMA: ONE TARGET, MULTIPLE WAYS TO REACH IT

Why has BCMA become such an important therapeutic target?


B-cell maturation antigen – BCMA – is preferentially expressed on plasma cells and malignant myeloma cells, making it an attractive target for immune-directed therapy.

Today, BCMA can be approached through different therapeutic platforms:



03 | THE ADC CONCEPT: PRECISION DELIVERY

Think of an antibody-drug conjugate as three components working together




In multiple myeloma, BCMA-directed antibody-drug conjugates have introduced a therapeutic approach that is distinct from cellular therapy and T-cell-engaging bispecific antibodies.

04 | THE NEW QUESTION IN RELAPSED MYELOMA

As treatment options expand, sequencing becomes increasingly important.



Consider:



In relapsed myeloma, innovation matters. Sequencing that innovation intelligently may matter just as much.

KEY REFERENCES — EDITION 1

- Hungria V, et al. Lancet Oncology. 2025;26:1067–1080. DREAMM-7 updated OS analysis.
- Dimopoulos MA, et al. N Engl J Med. 2024;391:408–421. DREAMM-8.
- Hungria V, et al. EHA 2026. Updated 4-year DREAMM-7 analysis.

For educational and awareness purposes only; this material is not intended as commercial promotion, medical advice, clinical proof, or a substitute for independent professional judgment.

Powered by